2022
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings
Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Research And Treatment 2022, 192: 201-210. PMID: 35066788, DOI: 10.1007/s10549-021-06494-z.Peer-Reviewed Original ResearchConceptsAdditional biospecimensMedical oncologistsBreast biopsyBreast tissueBiopsy resultsSingle academic medical centerBreast medical oncologistsPain/discomfortPerceptions of patientsMost medical oncologistsAbnormal breastDiagnostic breast biopsyAcademic medical centerPercutaneous breast biopsyNational Cancer InstituteDonation of bloodCancer CenterDiagnostic biopsyPercutaneous biopsyMedical CenterBiopsyCancer InstitutePatientsOncologistsProcedure risk
2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology 2014, 15: 1207-1214. PMID: 25218906, PMCID: PMC4294183, DOI: 10.1016/s1470-2045(14)70391-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialCisplatinConfidence IntervalsDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaximum Tolerated DoseMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhthalazinesPiperazinesQuinazolinesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsProgression-free survivalRecurrent platinum-sensitive ovarian cancerPlatinum-sensitive ovarian cancerPhase 2 studyOvarian cancerOlaparib monotherapyMedian progression-free survivalGermline BRCA statusPhase 2 dosePrimary peritoneal cancerRecurrent ovarian cancerPhase 2 trialPhase 3 trialSide effect profilePhase 1 trialUS academic medical centersPatient-reported outcomesEndometrioid ovarian cancerGermline BRCA1/2 mutationsAnti-angiogenic therapyAnti-angiogenic agentsCombination of olaparibAcademic medical centerNational Cancer InstituteVEGF receptor 1
2013
Prospective clinical experience with research biopsies in breast cancer patients.
Zeghibe C, Luis I, Frank E, Sohl J, Washington K, Silverman S, Fonte J, Mayer E, Overmoyer B, Richardson A, Krop I, Winer E, Lin N. Prospective clinical experience with research biopsies in breast cancer patients. Journal Of Clinical Oncology 2013, 31: e17574-e17574. DOI: 10.1200/jco.2013.31.15_suppl.e17574.Peer-Reviewed Original ResearchResearch biopsiesAdverse eventsBreast cancerCohort 1Cohort 2Grade 2Dana-Farber Cancer InstituteGrade 2 painGrade 3 painProspective clinical experienceSingle institution experienceTime of diagnosisBreast cancer patientsOngoing prospective studyMajority of ptsAcademic medical centerWithdrew consentAnalytic cohortChart reviewFirst recurrenceMetastatic diseasePerformance statusSevere painInstitution experienceProspective study